Compare Natera Inc. Common Stock (NTRA) vs PT Telekomunikasi Indonesia Tbk (TLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs PT Telekomunikasi Indonesia Tbk — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while PT Telekomunikasi Indonesia Tbk trades at $12.71 (market cap $12.31B). The key difference: Natera Inc. Common Stock is far larger — about 4.6× PT Telekomunikasi Indonesia Tbk's market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.66% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and PT Telekomunikasi Indonesia Tbk for 1 Days on average.
| NTRA | TLK | |
|---|---|---|
Market Cap | $57.03B | $12.31B |
Volume | 1,131,157 | 964,895 |
Sector | Health | Media |
52-Week High | $425.64 | $23.43 |
52-Week Low | $179.42 | $12.42 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $56.18B | $13.67B |
Dividend Yield | — | 9.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TLK trades at $12.65, down 1.02% on the day, with a bearish technical signal driven by moving averages. The stock shows mixed earnings performance with two recent misses but a Q2 2026 beat. Fundamentals remain solid with a 66.88% gross margin and attractive valuation at P/E of 12.72 and EV/EBITDA of 3.27. Recent news includes a 52-week low hit in September 2026 and institutional buying activity.
The outlook is cautious with 100% hold ratings from analysts and bearish technical indicators. Investment opportunity lies in deep value metrics and positive 5G developments, but risks include earnings volatility and competitive pressures in the telecommunications sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About PT Telekomunikasi Indonesia Tbk
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →
